The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Aristolochic acid as a probable human cancer hazard in herbal remedies: a review
Abstract
The old herbal drug aristolochic acid (AA), derived from Aristolochia spp., has been associated with the development of a novel nephropathy, designated aristolochic acid nephropathy (AAN), and urothelial cancer in AAN patients. There is clear evidence that the major components of the plant extract AA, aristolochic acid I (AAI) and aristolochic acid II (AAII), both nitrophenanthrene carboxylic acids, are genotoxic mutagens forming DNA adducts after metabolic activation through simple reduction of the nitro group. Several mammalian enzymes have been shown to be capable of activating both AAI and AAII in vitro and in cells. The activating metabolism has been elucidated and is consistent with the formation of a cyclic nitrenium ion with delocalized charge leading to the preferential formation of purine adducts bound to the exocyclic amino groups of deoxyadenosine and deoxyguanosine. The predominant DNA adduct in vivo, 7-(deoxyadenosin-N(6)-yl)aristolactam I (dA-AAI), which is the most persistent of the adducts in target tissue, is a mutagenic lesion leading to AT-->TA transversions in vitro. This transversion mutation is found at high frequency in codon 61 of the H-ras oncogene in tumours of rodents induced by AAI, suggesting that dA-AAI might be the critical lesion in the carcinogenic process in rodents. DNA-binding studies confirmed that both AAs bind to the adenines of codon 61 in the H-ras mouse gene and preferentially to purines in the human p53 gene. In contrast, the molecular mechanism of renal interstitial fibrosis in humans after chronic administration of AA remains to be explored. However, preliminary findings suggest that DNA damage by AA is not only responsible for the tumour development but also for the destructive fibrotic process in the kidney. It is concluded that there is significant evidence that AA is a powerful nephrotoxic and carcinogenic substance with an extremely short latency period, not only in animals but also in humans. In particular, the highly similar metabolic pathway of activation and resultant DNA adducts of AA allows the extrapolation of carcinogenesis data from laboratory animals to the human situation. Therefore, all products containing botanicals known to or suspected of containing AA should be banned from the market world wide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Preferential Formation of Benzo[ a ]pyrene Adducts at Lung Cancer Mutational Hotspots in P53
Denissenko, M. F., Pao, A., Tang, M.-S., & Pfeifer, G. P. (1996) · Science · doi:10.1126/science.274.5286.430 · Cited by 1,650
Vanherweghem, J.-L., Tielemans, C., Abramowicz, D., Depierreux, M., Vanhaelen-Fastre, R., Vanhaelen, M., Dratwa, M., Richard, C., Vandervelde, D., Verbeelen, D., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92984-2 · Cited by 1,076
Environment and Cancer: Who Are Susceptible?
Perera, F. P. (1997) · Science · doi:10.1126/science.278.5340.1068 · Cited by 638
Mutagenicity of Nitroaromatic Compounds
Purohit, V., & Basu, A. K. (2000) · Chemical Research in Toxicology · doi:10.1021/tx000002x · Cited by 450
Hussain, S. P., & Harris, C. C. (1998) · PubMed · Cited by 407
Oncogene Activation in Chemical Carcinogenesis
(1988) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60222-5 · Cited by 388
Identification of aristolochic acid in Chinese herbs
Vanhaelen, M., Vanhaelen-Fastre, R., But, P., & Vanherweghem, J.-L. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90964-4 · Cited by 344
Urothelial lesions in Chinese-herb nephropathy
Cosyns, J.-P., Jadoul, M., Squifflet, J.-P., Wese, F.-X., & van Ypersele de Strihou, C. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70136-8 · Cited by 306
Chinese herbs nephropathy: A clue to Balkan endemic nephropathy?
Cosyns, J.-P., Jadoul, M., Squifflet, J.-P., de Plaen, J.-F., Ferluga, D., & Van Ypersele de Strihou, C. (1994) · Kidney International · doi:10.1038/ki.1994.220 · Cited by 297
Cited by
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Aristolochic acid nephropathy: A worldwide problem
Debelle, F. D., Vanherweghem, J.-L., & Nortier, J. L. (2008) · Kidney International · doi:10.1038/ki.2008.129 · Cited by 763
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
Grollman, A. P., Shibutani, S., Moriya, M., Miller, F., Wu, L., Moll, U., Suzuki, N., Fernandes, A., Rosenquist, T., Medverec, Z., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701248104 · Cited by 606
From traditional Chinese medicine to rational cancer therapy
Efferth, T., Li, P. C. H., Konkimalla, V. S. B., & Kaina, B. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.07.001 · Cited by 528
Kovacic, P., & Somanathan, R. (2014) · Journal of Applied Toxicology · doi:10.1002/jat.2980 · Cited by 510
Challenges to effective cancer control in China, India, and Russia
Goss, P. E., Strasser-Weippl, K., Lee-Bychkovsky, B. L., Fan, L., Li, J., Chavarri-Guerra, Y., Liedke, P. E. R., Pramesh, C. S., Badovinac-Crnjevic, T., Sheikine, Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70029-4 · Cited by 496
Aristolochic acid-associated urothelial cancer in Taiwan
Chen, C.-H., Dickman, K. G., Moriya, M., Zavadil, J., Sidorenko, V. S., Edwards, K. L., Gnatenko, D. V., Wu, L., Turesky, R. J., Wu, X.-R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119920109 · Cited by 419
Jordan, S. A., Cunningham, D. G., & Marles, R. J. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.005 · Cited by 415
“The history and evolution of this issue has been reviewed (Arlt et al., 2002, Cosyns, 2003), most recently by Debelle et al. (2008), and will not be reviewed further here.”
BackgroundRat toxicogenomic study reveals analytical consistency across microarray platforms
Guo, L., Lobenhofer, E. K., Wang, C., Shippy, R., Harris, S. C., Zhang, L., Mei, N., Chen, T., Herman, D., Goodsaid, F. M., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1238 · Cited by 406
Hypermutation in human cancer genomes: footprints and mechanisms
Roberts, S. A., & Gordenin, D. A. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3816 · Cited by 405
Exome sequencing of hepatitis B virus–associated hepatocellular carcinoma
Huang, J., Deng, Q., Wang, Q., Li, K.-Y., Dai, J.-H., Li, N., Zhu, Z.-D., Zhou, B., Liu, X.-Y., Liu, R.-F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2391 · Cited by 385
The chemistry of isoindole natural products
Speck, K., & Magauer, T. (2013) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.9.243 · Cited by 383
Barnes, J. L., Zubair, M., John, K., Poirier, M. C., & Martin, F. L. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180519 · Cited by 318
A renaissance in herbal medicine identification: From morphology to DNA
Chen, S., Pang, X., Song, J., Shi, L., Yao, H., Han, J., & Leon, C. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.07.004 · Cited by 302
Aristolochic Acid and ???Chinese Herbs Nephropathy???: A Review of the Evidence to Date
Cosyns, J.-P. (2003) · Drug Safety · doi:10.2165/00002018-200326010-00004 · Cited by 286
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028812 · Cited by 274
Heinrich, M., Chan, J., Wanke, S., Neinhuis, C., & Simmonds, M. S. J. (2009) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.05.028 · Cited by 273
Herbal bioactivation: The good, the bad and the ugly
Zhou, S., Koh, H.-L., Gao, Y., Gong, Z.-Y., & Lee, E. J. D. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.09.035 · Cited by 256
Botanical Medicines — The Need for New Regulations
Marcus, D. M., & Grollman, A. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmsb022858 · Cited by 253
Toxic phytochemicals and their potential risks for human cancer
Bode, A. M., & Dong, Z. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0160 · Cited by 140
Geck, M. S., Cristians, S., Berger-González, M., Casu, L., Heinrich, M., & Leonti, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01160 · Cited by 74
Metadata
- Authors
- Arlt, V. M.
- Venue
- Mutagenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-07-01
- Volume
- 17
- Issue
- 4
- Pages
- 265-277
- ISSN
- 0267-8357 (ISSN-L)
- 1464-3804
- OpenAlex
- W2162463986
- Cited by
- 505
- References
- 54
- FWCI
- 12.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.